Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations

Clinical trial NCT02383927 · COMPLETED

Trial details

NCT number: NCT02383927
Sponsor: Kura Oncology, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Thyroid Cancer Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)HRAS Mutant Tumor Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Start date: 2015-05-13
Primary completion: 2020-12-14
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.